Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL639531 | 0.95 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2PPARA | |
| SCHEMBL4823073 | 0.93 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2PPARA | |
| SCHEMBL4339424 | 0.93 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2PPARA | |
| SCHEMBL17641091 | 0.93 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2PPARA | |
| SCHEMBL4823593 | 0.93 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2PPARA | |
| SCHEMBL25357815 | 0.93 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2PPARA | |
| SCHEMBL1765926 | 0.93 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2PPARA | |
| SCHEMBL18257718 | 0.93 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2PPARA | |
| SCHEMBL31528885 | 0.93 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2PPARA | |
| SCHEMBL30438065 | 0.93 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577258-B2 | Macrocyclic compound | VERNALIS (R&D) LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-20250296946-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2025-09-25 | — | — | US | disclosed |
| US-12365704-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4223368-B1 | MACROCYCLIC COMPOUNDS INCORPORATING PIPERIDINE AND QUINOLINE OR QUNAXOLINE AS IRAK-4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | ASAHI KASEI PHARMA CORP (JP) | 2025-05-21 | — | — | EP | disclosed |
| CN-119790058-A | Fused cyclic KRAS inhibitors for the treatment of diseases | 荣山医药股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| EP-4476230-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-116348472-B | Macrocyclic compounds | 旭化成制药株式会社 | 2024-12-03 | — | — | CN | disclosed |
| US-20240276957-A1 | METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS | AGIOS PHARMACEUTICALS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4281463-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN Pharmaceutica NV (BE) | 2023-11-29 | — | — | EP | disclosed |
| US-20230357271-A1 | MACROCYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-11-09 | — | — | US | disclosed |
| EP-1123936-A1 | FUSED PYRIDAZINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2001-08-16 | — | — | EP | disclosed |
| EP-1112275-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | Metabasis Therapeutics, Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6248740-B1 | FOR SUPPRESSION OF HISTAMINE OR EOSINOPHIL CHEMOTAXIS TO TREAT ASTHMA; ANTIALLERGENIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| WO-2000014095-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
| EP-0979231-A1 | CONDENSED PYRIDAZINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-02-16 | — | — | EP | disclosed |
| WO-1998049167-A1 | CONDENSED PYRIDAZINE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-05 | — | — | WO | disclosed |
| EP-0711362-B1 | TAG REAGENT AND ASSAY METHOD | OXFORD GENE TECHNOLOGY LIMITED (GB) | 1997-10-29 | — | — | EP | disclosed |
| EP-0778280-A2 | Tag reagent and assay method | ISIS INNOVATION LIMITED (GB) | 1997-06-11 | — | — | EP | disclosed |
| EP-0711362-A1 | TAG REAGENT AND ASSAY METHOD | ISIS INNOVATION (GB) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004160-A1 | TAG REAGENT AND ASSAY METHOD | ISIS INNOVATION LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365704-B2 | Nucleic acid-polypeptide compositions and uses thereof | POLM, POLN, POLI | SMYD2 3428/4885CYP3A4 4860/4885HTT 1038/4885 |
| US-12577258-B2 | Macrocyclic compound | IRAK1, IRAK4, IRAK2 | SMYD2 3690/4885CYP3A4 3541/4885HTT 3431/4885 |
| US-20230357271-A1 | MACROCYCLIC COMPOUND | IRAK4, IRAK1, IRAK2 | SMYD2 2843/4885CYP3A4 2757/4885HTT 4092/4885 |
| US-20250296946-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | SMYD2 3428/4885CYP3A4 4860/4885HTT 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.